Literature DB >> 2174357

Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.

E Priel1, S D Showalter, M Roberts, S Oroszlan, S Segal, M Aboud, D G Blair.   

Abstract

In the present study, we found a topoisomerase I (topo I) activity in two strains of human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus (EIAV) particles. The topo I activity was located in the EIAV cores and differed from the cellular topo I in its ionic requirements and response to ATP, indicating that these were two distinct forms of this enzyme. Topo I activity was removed from the viral lysates and viral cores by anti-topo I antiserum. The only protein recognized by this antiserum was an 11.5 kd protein in HIV lysate and 11 kd in EIAV lysate. We showed that the 11 kd protein recognized by the anti-topo I antiserum is the EIAV p11 nucleocapsid protein. Furthermore, purified topo I protein blocked the binding of the antibodies to the p11 protein and vice versa, purified p11 protein blocked the binding of these antibodies to the cellular topo I. These results suggest that the EIAV p11 nucleocapsid protein and the cellular topo I share similar epitopes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174357      PMCID: PMC552192          DOI: 10.1002/j.1460-2075.1990.tb07640.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  31 in total

1.  The preparation and biochemical characterization of intact capsids of equine infectious anemia virus.

Authors:  M M Roberts; S Oroszlan
Journal:  Biochem Biophys Res Commun       Date:  1989-04-28       Impact factor: 3.575

Review 2.  RNA-directed DNA synthesis and RNA tumor viruses.

Authors:  H M Temin; D Baltimore
Journal:  Adv Virus Res       Date:  1972       Impact factor: 9.937

3.  DNA topoisomerase activity associated with Rous sarcoma virus.

Authors:  J H Weis; A J Faras
Journal:  Virology       Date:  1981-10-30       Impact factor: 3.616

4.  Purification and characterization of Xenopus laevis type I topoisomerase.

Authors:  D G Attardi; A De Paolis; G P Tocchini-Valentini
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

5.  Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi's anaemia.

Authors:  B Auer; H P Vosberg; U Buhre; H Klocker; M Hirsch-Kauffmann; M Schweiger
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

6.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors:  J Vieira; J Messing
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

7.  Isolation and partial characterization of two distinct DNA topoisomerases from cauliflower inflorescence.

Authors:  H Fukata; H Fukasawa
Journal:  J Biochem       Date:  1982-04       Impact factor: 3.387

8.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

9.  Higher order metaphase chromosome structure: evidence for metalloprotein interactions.

Authors:  C D Lewis; U K Laemmli
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

10.  Purification and characterization of wheat germ DNA topoisomerase I (nicking-closing enzyme).

Authors:  W S Dynan; J J Jendrisak; D A Hager; R R Burgess
Journal:  J Biol Chem       Date:  1981-06-10       Impact factor: 5.157

View more
  12 in total

1.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.

Authors:  E Priel; S D Showalter; M Roberts; S Oroszlan; D G Blair
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity.

Authors:  Cagan Gurer; Anders Höglund; Stefan Höglund; Jeremy Luban
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 5.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

6.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  C Ulich; A Dunne; E Parry; C W Hooker; R B Gaynor; D Harrich
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Inhibition of retrovirus-induced disease in mice by camptothecin.

Authors:  E Priel; E Aflalo; G Chechelnitsky; D Benharroch; M Aboud; S Segal
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses.

Authors:  J W Bess; P J Powell; H J Issaq; L J Schumack; M K Grimes; L E Henderson; L O Arthur
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.

Authors:  H Takahashi; M Matsuda; A Kojima; T Sata; T Andoh; T Kurata; K Nagashima; W W Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.